Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
65.42 USD +0.23% Intraday chart for Gilead Sciences, Inc. -2.01% -19.24%
Apr. 26 TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Apr. 26 Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82,209 73,031 91,081 107,677 100,942 81,577 - -
Enterprise Value (EV) 1 82,450 103,910 118,530 126,522 118,665 98,461 90,862 85,349
P/E ratio 15.4 x 583 x 14.7 x 23.6 x 18 x 94.4 x 12.4 x 11.6 x
Yield 3.88% 4.67% 3.91% 3.4% 3.7% 4.75% 4.96% 5.16%
Capitalization / Revenue 3.66 x 2.96 x 3.34 x 3.95 x 3.72 x 2.96 x 2.91 x 2.84 x
EV / Revenue 3.67 x 4.21 x 4.34 x 4.64 x 4.38 x 3.58 x 3.25 x 2.97 x
EV / EBITDA 6.61 x 7.88 x 8.12 x 8.86 x 9.01 x 10.3 x 6.51 x 6.03 x
EV / FCF 9.91 x 13.8 x 11 x 15.2 x 16 x 11.3 x 9.73 x 8.65 x
FCF Yield 10.1% 7.24% 9.12% 6.59% 6.25% 8.84% 10.3% 11.6%
Price to Book 3.65 x 4.04 x 4.32 x 5.05 x 4.48 x 3.55 x 3.15 x 2.81 x
Nbr of stocks (in thousands) 1,265,146 1,253,528 1,254,384 1,254,244 1,246,042 1,246,969 - -
Reference price 2 64.98 58.26 72.61 85.85 81.01 65.42 65.42 65.42
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,449 24,689 27,305 27,281 27,116 27,540 27,999 28,731
EBITDA 1 12,468 13,184 14,598 14,283 13,177 9,521 13,968 14,144
EBIT 1 11,064 11,704 12,548 12,180 10,484 7,303 11,642 12,067
Operating Margin 49.29% 47.41% 45.95% 44.65% 38.66% 26.52% 41.58% 42%
Earnings before Tax (EBT) 1 5,160 1,669 8,278 5,814 6,859 4,238 8,629 8,929
Net income 1 5,386 123 6,225 4,592 5,665 391 6,433 6,679
Net margin 23.99% 0.5% 22.8% 16.83% 20.89% 1.42% 22.97% 23.25%
EPS 2 4.220 0.1000 4.930 3.640 4.500 0.6933 5.285 5.624
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,702 9,335 9,866
FCF margin 37.06% 30.45% 39.57% 30.59% 27.37% 31.6% 33.34% 34.34%
FCF Conversion (EBITDA) 66.72% 57.02% 74.02% 58.42% 56.32% 91.39% 66.83% 69.75%
FCF Conversion (Net income) 154.46% 6,112.2% 173.57% 181.71% 131% 2,225.45% 145.12% 147.71%
Dividend per Share 2 2.520 2.720 2.840 2.920 3.000 3.110 3.246 3.376
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 7,421 7,244 6,590 6,260 7,042 7,389 6,352 6,599 7,051 7,115 6,686 6,758 7,008 7,216 6,559
EBITDA 1 4,902 2,042 4,049 3,195 3,811 3,227 2,883 3,258 3,908 3,427 -889.3 3,349 3,384 3,555 -
EBIT 1 4,379 1,507 3,524 2,670 3,286 2,699 2,243 2,277 3,224 2,739 -1,117 2,672 2,900 2,893 2,685
Operating Margin 59.01% 20.8% 53.47% 42.65% 46.66% 36.53% 35.31% 34.51% 45.72% 38.5% -16.71% 39.54% 41.38% 40.09% 40.93%
Earnings before Tax (EBT) 3,438 759 -152 1,503 2,432 2,031 1,300 1,588 2,318 1,653 -4,486 2,062 2,160 2,066 -
Net income 1 2,592 382 19 1,144 1,789 1,640 1,010 1,045 2,180 1,429 -4,170 1,580 1,622 1,563 -
Net margin 34.93% 5.27% 0.29% 18.27% 25.4% 22.2% 15.9% 15.84% 30.92% 20.08% -62.37% 23.38% 23.14% 21.66% -
EPS 2 2.050 0.3000 0.0200 0.9100 1.420 1.300 0.8000 0.8300 1.730 1.140 -3.340 1.174 1.236 1.278 1.075
Dividend per Share 2 0.7100 0.7100 0.7300 0.7300 0.7300 0.7300 0.7500 0.7500 0.7500 0.7500 0.7600 0.7700 0.7700 0.7700 0.7633
Announcement Date 10/28/21 2/1/22 4/28/22 8/2/22 10/27/22 2/2/23 4/27/23 8/3/23 11/7/23 2/6/24 4/25/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 241 30,879 27,449 18,845 17,723 16,885 9,285 3,772
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.0193 x 2.342 x 1.88 x 1.319 x 1.345 x 1.773 x 0.6648 x 0.2667 x
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,702 9,335 9,866
ROE (net income / shareholders' equity) 38.3% 43.8% 46.8% 43.3% 38.5% 21.3% 35.5% 32.1%
ROA (Net income/ Total Assets) 8.6% 0.19% 9.13% 14% 13.5% 7.73% 12.8% 12.8%
Assets 1 62,651 65,079 68,180 32,874 41,980 5,057 50,330 52,256
Book Value Per Share 2 17.80 14.40 16.80 17.00 18.10 18.40 20.70 23.30
Cash Flow per Share 2 7.160 6.470 9.020 7.190 6.360 3.300 7.730 8.430
Capex 1 825 650 579 728 585 600 712 720
Capex / Sales 3.67% 2.63% 2.12% 2.67% 2.16% 2.18% 2.54% 2.51%
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.42 USD
Average target price
84.22 USD
Spread / Average Target
+28.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-19.24% 81.39B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 653B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 296B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 233B
NOVARTIS AG Stock Novartis AG
+5.46% 201B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 193B
AMGEN INC. Stock Amgen Inc.
-6.26% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Financials Gilead Sciences, Inc.